Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
Does Medicare Cover Horizant?
Most Medicare Part D plans cover Horizant (gabapentin enacarbil) at Tier 4 with prior authorization required. Coverage is on the formulary but not automatic: the plan approves it only after a PA submission documents an FDA-approved indication (RLS or PHN), the correct ICD-10 code, step therapy history, and the FDA non-interchangeability statement. The workflow below follows a Horizant PA from eligibility check through approval or appeal.
Quick Answer: Getting Medicare Approval for Horizant
Quick answer: To get Medicare approval for Horizant (gabapentin enacarbil), confirm the plan covers it for the FDA-approved indications (moderate-to-severe primary restless legs syndrome or postherpetic neuralgia), then submit a PA request with the ICD-10 code (G25.81 for RLS or B02.29 for PHN), step-therapy documentation showing trial or intolerance of immediate-release gabapentin or pregabalin, and a signed medical necessity letter from the prescriber. Under CMS-0057-F, standard Medicare PA decisions arrive within 7 calendar days (urgent within 72 hours).
Does Medicare Cover Horizant? What You Need to Know First
Most Medicare Part D plans cover Horizant at Tier 4 (specialty or non-preferred brand) with prior authorization required. Coverage exists on most formularies, but it is not automatic. The documentation you submit activates coverage, and without the right documentation, the claim will be denied even though the drug is technically on the plan’s formulary.
Part D plans set their own formularies within CMS guidelines. Because Horizant has no FDA-approved generic equivalent, pharmacies cannot substitute generic gabapentin for Horizant at the dispensing level. The two drugs are pharmacologically different and produce different blood levels. However, most Part D plans still require patients to try generic gabapentin before approving Horizant under PA. This creates a clinical tension that your PA submission must address directly: generic gabapentin was tried, produced inadequate results or side effects, and Horizant’s different absorption profile makes it the appropriate next step.
Medicare Advantage plans follow similar coverage rules but vary significantly by private insurer. UnitedHealthcare, Humana, Aetna, and BCBS MA plans each have different step therapy requirements, different documentation expectations, and different portal systems. In 2026, CMS requires all MA plans to decide standard PAs within 7 calendar days and urgent requests within 72 hours under CMS-0057-F. This timeline applies uniformly, but the documentation requirements remain plan-specific.
Medication Overview — Horizant (Gabapentin Enacarbil)
Horizant is an extended-release prodrug of gabapentin that uses a transporter-mediated absorption mechanism in the GI tract. This mechanism produces predictable, sustained plasma concentrations that differ significantly from generic gabapentin’s erratic absorption profile. Generic gabapentin has dose-dependent, saturable absorption, meaning higher doses produce proportionally lower blood levels. Horizant’s absorption mechanism avoids this limitation, which is why the FDA explicitly states the two are not interchangeable.
FDA-approved indications: Moderate-to-severe restless legs syndrome (RLS) in adults, and management of postherpetic neuralgia (PHN) in adults. These are the only two approved indications, and PA submissions for off-label uses will face higher denial rates.
FDA prescribing note (2025 label): “HORIZANT is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles.” This single sentence from the FDA label is the strongest argument in any Horizant PA. It establishes that a failed generic gabapentin trial does not mean Horizant will fail, because the two drugs behave differently in the body.
Dosing: For RLS: 600 mg once daily taken with food at approximately 5 PM. The timing matters clinically because RLS symptoms peak in the evening. For PHN: 600 mg once daily on Days 1-3, then 600 mg twice daily. Accurate dosing information on the PA form prevents quantity limit questions.
Save 40-70% with dedicated Healthcare specialists
Book a 15-minute call. We will map your current healthcare outsourcing workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
Key Takeaways Before You Start the PA
- ICD-10: G25.81 (RLS), B02.29 (PHN). M79.2 as secondary only.
- Step therapy documentation for prior generic gabapentin or dopamine agonist trials
- Non-interchangeability argument from FDA prescribing information
- Electronic portal submission for faster turnaround
- Timeline: 7 calendar days (standard), 72 hours (urgent) under 2026 CMS rules
- Renewal trigger: 30 days before PA expiration. Most run 6-12 months.
The 7-Step Medicare Prior Authorization Process for Horizant
Step 1: Gather Patient Information. Collect the patient’s full legal name as it appears on their Medicare card, Medicare Beneficiary Identifier (MBI, not the legacy HICN), date of birth, gender, and the specific Part D plan name and plan ID. Verify the plan is active before proceeding. If the patient recently changed plans during open enrollment, confirm the new plan’s effective date covers the intended service date.
Step 2: Document Prescriber Information. Enter the prescribing physician’s individual NPI (not the group NPI), full name, specialty designation, clinic address, phone, and fax. Some plans require the prescriber to be a neurologist or sleep medicine specialist for RLS PA approval. If the prescriber is a primary care physician, check the plan’s prescriber requirements before submission to avoid a denial based on prescriber specialty.
Step 3: Specify Medication Details. Enter “Horizant (gabapentin enacarbil) 600 mg Extended-Release Tablets” using the brand name and generic name together. Include the exact dose per administration, frequency (once daily for RLS, twice daily for PHN maintenance), quantity per 30-day supply (30 tablets for RLS, 60 for PHN), and anticipated therapy duration. Being precise on quantity prevents quantity limit PA triggers that add processing time.
Step 4: Enter Correct Diagnosis Code. Use G25.81 for restless legs syndrome. Use B02.29 for postherpetic neuralgia. Do not use M79.2 (neuralgia and neuritis, unspecified) as the primary code for RLS. M79.2 alone triggers rejection on most payer auto-adjudication systems because it does not identify the specific condition. If M79.2 is relevant, list it as a secondary code with G25.81 as primary.
Step 5: Select Request Type. Standard processing (7 calendar days under 2026 CMS rules) is appropriate for most RLS PA requests. Select expedited or urgent processing (72 hours) for PHN patients with severe acute pain where treatment delay causes significant functional impairment. Document the clinical urgency in the request to support the expedited designation.
Step 6: Attach Clinical Documentation. Include: diagnosis documentation showing symptom severity and functional impact on sleep and daily activities, step therapy evidence showing prior gabapentin or pregabalin trial with specific dates, doses, duration, and documented outcomes, the FDA non-interchangeability statement copied directly from the prescribing information, a letter of medical necessity explaining why Horizant specifically is needed for this patient, and a prior treatment timeline table listing all medications tried in chronological order. This documentation package should tell a complete story that a reviewer can follow from initial treatment through current prescription.
Step 7: Submit Electronically. Use the plan’s provider portal or CoverMyMeds. Do not fax unless the plan has no electronic option. Log the confirmation number, submission date, and time. Set a follow-up reminder for business day 5 if no decision has been received.
ICD-10 and Coding Compliance for Horizant PA Requests
CPT codes are not required for Part D drug PA. Using M79.2 alone when G25.81 exists weakens the case and can trigger rejection.
Step Therapy — What Payers Require Before Approving Horizant
For RLS: The typical step therapy path requires a documented generic gabapentin trial lasting 4-8 weeks at a therapeutic dose with documented failure, intolerance, or inadequate response. Some plans add a second step requiring a dopamine agonist trial (pramipexole or ropinirole). If the patient experienced dopamine augmentation, a well-documented phenomenon where dopamine agonists make RLS symptoms worse over time, this documented complication bypasses the agonist step on most plans. Augmentation is a recognized clinical concern in RLS treatment guidelines, and payer medical directors are generally familiar with it. A medical exception is available for patients with documented contraindications to gabapentin (renal insufficiency requiring dose adjustment, severe sedation, or cognitive effects in elderly patients).
For PHN: Step 1 typically requires a trial of generic gabapentin or pregabalin at therapeutic doses with documented inadequate pain control. For elderly patients (65+), polypharmacy concerns and fall risk from gabapentin’s sedation profile often support exception requests. Document the patient’s concurrent medications, fall history, and renal function to build the clinical case for Horizant’s once-daily dosing advantage.
Key argument: The FDA explicitly states Horizant is not interchangeable with other gabapentin products. This supports the clinical position that a failed generic gabapentin trial does not predict Horizant’s outcome because the two drugs have fundamentally different absorption and pharmacokinetic profiles. Include this FDA language in every submission and appeal.
Medicare Advantage Plans in Florida, Texas, and Ohio
Florida: Highest MA enrollment nationally. WellCare and Humana Gold Plus require failed gabapentin AND dopamine agonist for RLS. FL is NOT in the 2026 Traditional Medicare PA pilot. 7-day/72-hour timelines apply under CMS rules.
Texas: 2026 PA pilot state (outpatient procedures only, not Part D drugs). BCBS TX is receptive to the FDA non-interchangeability argument. Documented augmentation from dopamine agonists is the most effective bypass.
Ohio: Also a 2026 PA pilot state (procedures, not Part D). UHC, Humana, Aetna, Medical Mutual, SummaCare: documented RLS diagnosis, failed gabapentin/pregabalin trial, prescriber attestation. Some require dopamine agonist failure.
What to Do When a Horizant PA Is Denied
80.7% of appealed Medicare Advantage denials are overturned (KFF 2025).
Step 1: Read the denial reason carefully. Common denial reasons include step therapy not met (the plan requires documented failure of generic gabapentin or a dopamine agonist before approving Horizant), diagnosis code mismatch (M79.2 used as primary instead of G25.81 or B02.29), insufficient documentation (missing physician narrative or incomplete treatment history), and formulary exclusion (the drug is not on the plan’s covered list at all). The denial letter must now provide specific clinical rationale under CMS-0057-F. If it does not, document this gap and cite it in your appeal.
Step 2: Distinguish between a formulary exception request and a PA appeal. These are separate processes with different forms and different review criteria. A formulary exception asks the plan to cover a drug that is not on its formulary. A PA appeal challenges a denial for a drug that IS on the formulary but was denied for other reasons. Submitting through the wrong channel delays the response by days or weeks.
Step 3: Reinforce documentation with targeted additions. Attach the FDA non-interchangeability language from the prescribing information. Include updated clinical notes documenting symptom severity and functional impact since the last submission. Write a stronger letter of medical necessity that specifically addresses each stated denial reason rather than repeating the original submission language. If step therapy was the denial basis, provide detailed dates, doses, and documented outcomes for every prior medication trial.
Step 4: Request expedited appeal if clinically urgent. For patients with severe RLS symptoms disrupting sleep and daily function, or PHN patients with uncontrolled pain, the 72-hour expedited timeline applies. Document the clinical urgency in the appeal request with specific functional impact statements from the treating physician.
Step 5: Escalate to the Independent Review Entity (IRE) if the first-level appeal is denied. For Medicare Advantage plans, the IRE is Maximus. The IRE reviews the case independently and its decision is binding on the plan. Include all prior documentation plus any new clinical information. The IRE process adds time but has a strong overturn rate when clinical documentation supports the request.
How Staffingly Manages Horizant Prior Authorizations at $399/week (volume discounts to $299/week)
Staffingly handles Medicare PAs for 800+ providers. Our teams manage Horizant and specialty drug PAs at $399/week (volume discounts to $299/week), a 70% savings compared to in-house staff.
- Eligibility verification against the patient’s specific Part D plan
- Correct ICD-10 selection (G25.81 for RLS, B02.29 for PHN)
- Step therapy documentation review before submitting
- FDA non-interchangeability language attached to every initial PA
- Electronic submission through plan portals or CoverMyMeds
- PA tracking with automatic renewal triggers 30 days before expiration
- Appeal management if denied
- SOC 2 Type II, HITRUST, ISO 27001, HIPAA compliant
Go-live in 48-72 hours. Clean claim rate: 99.2%.
Frequently Asked Questions About Medicare Approval for Horizant
Q1: Does Medicare cover Horizant under Part D? A: Most Part D plans cover Horizant at Tier 4 with PA required. Check the specific plan’s formulary. A small number may exclude it entirely, requiring a formulary exception.
Q2: How long does Medicare take to process a Horizant PA? A: Under 2026 CMS rules, MA plans must decide within 7 calendar days (standard) or 72 hours (urgent). Electronic submission shortens turnaround.
Q3: What if the PA is denied? A: 80.7% of appealed MA denials are overturned. File first-level appeal, request formulary exception for step therapy bypass, or escalate to IRE.
Q4: Can Medicare substitute generic gabapentin for Horizant? A: No. The FDA label explicitly states it is not interchangeable. However, PA may require documented failure of generic gabapentin as a separate issue from pharmacy substitution.
Q5: Does the $2,100 Part D OOP cap help Horizant patients? A: Yes. At Tier 4 copays of $80-$120/month, patients may reach the cap by mid-year, then pay $0 for remaining Part D drugs. The donut hole was eliminated effective 2025.
Q6: Is a CPT code needed? A: No. Part D PA uses ICD-10 codes. G25.81 for RLS, B02.29 for PHN.
Q7: What about Medicare plus commercial secondary? A: You must satisfy Medicare Part D PA requirements for the primary payer. Some secondary plans cover Tier 4 cost-share but neither waives the other’s PA requirement.
What Did We Learn?
Getting Medicare approval for Horizant is a documentation exercise. The drug is covered under most Part D plans, but PA with step therapy, specific ICD-10 codes, and supporting documentation must be satisfied.
Most common failures: wrong ICD-10 code (using M79.2 instead of G25.81 or B02.29), missing step therapy documentation (no dates, doses, or outcomes for prior gabapentin trial), no FDA non-interchangeability language (the single strongest supporting argument available), or submitting by fax instead of electronic portal (adding days to the processing timeline). The appeal process is severely underused: 80.7% of appeals succeed, yet fewer than 11% of patients actually file one. Every denied Horizant PA that is not appealed represents a patient who either goes without treatment or pays retail for a medication their plan should cover.
For practices prescribing Horizant to multiple patients, building a Horizant-specific PA template with pre-populated documentation elements saves significant staff time. The template should include the FDA non-interchangeability language, a step therapy documentation table with columns for medication name, start date, end date, maximum dose, and outcome, and a letter of medical necessity framework that can be customized for each patient.
Staffingly manages Medicare PAs for 800+ providers at $399/week (volume discounts to $299/week), with 99.2% clean claim rate and 48-72 hour go-live.
Ready to Cut Prior Authorization and Eligibility Headaches?
Staffingly helps practices like yours get paid faster with a 99.2% clean-claim rate, 65-70% cost savings, and 48-72 hour go-live. SOC 2 Type II, HITRUST, and ISO 27001 certified. HIPAA compliant. MGMA Corporate Member.
- Start a 15-Day Risk-Free Pilot and see results before you commit.
- Call us: (800) 489-5877
